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Background: Streptococcus pneumoniae is the leading cause of community–acquired pneumonia in Africa.
Antimicrobial resistance of S. pneumoniae to penicillin and other commonly used antibiotics has increased
worldwide. However, prevalence data from the African region are sparse, especially with regard to adults.
Findings: In this study, adult patients presenting at an urban referral hospital in central Mozambique were
screened for pneumococcal pneumonia during an 8-week period in 2010: Patients with a respiratory syndrome
underwent chest radiography and a sputum sample was collected for pneumococcal culture and antimicrobial
susceptibility testing. A urine sample was tested for the presence of pneumococcal antigen.
177 patients with a respiratory syndrome were included. Overall, 41/177 (23%) patients fulfilled criteria for definite
or probable pneumococcal pneumonia and in the group of patients with a positive chest x-ray this concerned
35/86 (41%) patients. 166 sputum cultures yielded 16 pneumococcal strains. One mg oxacillin disc testing identified
potential penicillin resistance in 7/16 (44%) strains. Penicillin minimal inhibitory concentrations (MICs) were
measured for 15 of these strains and ranged from <0.016-0.75 mg/L. No MICs >2 mg/L were found, but 3/15 (20%)
pneumococcal strains had MICs >0.5 mg/L. All pneumococci were sensitive to erythromycin as measured by disc
diffusion testing, whereas 44% was resistant to trimethoprim-sulfametoxazole.
Conclusions: The proportion of pneumonia cases attributable to pneumococcus appeared to be high. Whilst none
of the S. pneumoniae strains tested were penicillin resistant, standard penicillin dosing for pneumonia may be
insufficient given the observed range of pneumococcal penicillin MICs.
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Background
Streptococcus pneumoniae is the leading cause of
community-acquired pneumonia around the world and in
Africa [1]. Severe pneumococcal disease, for which HIV is
a major risk factor, is associated with a high mortality in
African adults [2,3].* Correspondence: j.c.bos@amc.nl
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reproduction in any medium, provided the orAntimicrobial resistance of S. pneumoniae against the
most commonly used antimicrobial drugs is increasing
worldwide, principally affecting β-lactam, macrolide and
sulfonamide sensitivity [4]. In Africa, β-lactam antibi-
otics, and penicillin in particular, are amongst the
most widely used antimicrobial drugs for empirical
treatment of pneumonia. However, African antimicro-
bial resistance data are scarce, especially when con-
cerning adults [5,6].
We investigated the prevalence of penicillin resistance
of S. pneumoniae in adults with pneumococcal pneumonia
presenting in an urban hospital in central Mozambique.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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Study area
Our study was conducted at the Beira Central Hospital
(Hospital Central da Beira: HCB), a 932-bed govern-
mental referral health facility with 260 internal medicine
beds, located in the coastal capital of the central Sofala
province of the sub-Saharan African Mozambique. The
HIV prevalence among adult women in this region was
found to be 22.9% in 2009 [7]. Mozambique also ranks
amongst the countries with the highest tuberculosis bur-
den, with an estimated 409 new cases per 100,000 pop/
year. Pneumococcal vaccination of infants as part of the
Mozambican National Immunization Programme only
started in April 2013.Study design
We carried out a cross-sectional study among adults
(≥ 16 years) presenting at the HCB emergency room
with a respiratory syndrome. A respiratory syndrome
was defined as fever (axillary body temperature ≥37.5°C)
in combination with one or more of the following com-
plaints: cough with or without sputum production, dys-
pnoea and chest pain. Study participants were recruited
prospectively during a study period of 8 weeks, from
April to June 2010. A posterior-anterior chest x-ray
(CXR) was made immediately after presentation and
subsequently digitalized for review by an experienced,
external pulmonologist, who was blinded to the study
participant’s clinical data and pneumococcal test results.
Written informed consent was obtained from each pa-
tient before study entry. Ethical approval was obtained
from the Mozambican National Committee of Bio-ethics,
through its sub-committee seated in Beira (ref.: 007/10/
SBCE).Study procedures
Sputum samples were collected from all patients for
pneumococcal culture and sensitivity testing. Patients
were carefully instructed about how to provide a good-
quality sputum sample in a standardized way and study
staff directly observed the sputum production process for
all study participants. Sputum was inoculated on selective
Columbia CNA sheep blood agar plates (bioMérieux SA,
Marcy l’Etoile, France). Plates were incubated overnight
at 35–37°C in a candle jar after placement of a 5 μg opto-
chin disc (Oxoid Ltd., Cambridge, UK). Colonies sus-
pected for pneumococcus, on the basis of colony
morphology and optochin susceptibility as per manufac-
turer’s instructions, were subcultured on sheep blood
agar plates (bioMérieux SA, Marcy l’Etoile, France). The
Dryspot Pneumo latex agglutination test (Oxoid Ltd.,
Cambridge, UK) was used as per manufacturer’s instruc-
tions for final identification.Antimicrobial susceptibility of pneumococcal isolates
against oxacillin (1 μg), trimethoprim-sulfamethoxazole
(co-trimoxazole: 5.2-240 μg) and erythromycin (78 μg)
was tested using disc diffusion method (Neo-Sensitabs,
Rosco Diagnostica, Taastrup, Denmark). Zone diameter
breakpoint interpretation was done according to Euro-
pean Committee on Antimicrobial Susceptibility Testing
(EUCAST) recommendations as recommended by the
manufacturer. The benzyl penicillin minimal inhibitory
concentration (MIC) was measured using E-test strips
(bioMérieux SA, Marcy l’Etoile, France). Clinical break-
point interpretation of these MICs was done using the
EUCAST clinical breakpoint tables for interpretation of
MICs, using the recommendations for non-meningeal
infections: MIC ≤ 0.06 mg/L: susceptible; > 2 mg/L: re-
sistant; > 0.06 and ≤ 2 mg/L: intermediate category with
dose specific breakpoints [8].
A urine sample was collected from all patients for
urinary pneumococcal antigen testing using Binax NOW
S. pneumoniae, according to the manufacturer’s instruc-
tions (Binax Inc., Portland, ME, USA; currently manu-
factured by Alere Inc., Waltham, MA, USA).
Data analysis
In the absence of a ‘gold standard’ definition of (sus-
pected, pneumococcal) pneumonia and given the lack of
state-of-the-art blood culture capacity at the study site,
the following definitions were used. Suspected pneumo-
nia was defined as a respiratory syndrome combined
with a positive CXR, as defined by showing evidence of
any consolidation, and/or pleural effusion, and/or inter-
stitial disease. Definite pneumococcal pneumonia was
defined as a respiratory syndrome in combination with a
positive CXR and a positive sputum culture with S.
pneumoniae. Probable pneumococcal pneumonia was
defined as a respiratory syndrome in combination with a
positive CXR and a positive ICT. In the absence of a
CXR, or whenever a CXR was not positive, a respiratory
syndrome with a positive sputum culture with S. pneu-
moniae AND a positive ICT was also defined as a prob-
able pneumococcal pneumonia (Figure 1).
Data were entered and analysed using the Epi Info
package version 2002 (CDC, Atlanta, GA).
Results
Study population
177 patients were screened. 97/177 (55%) patients were
female and 150/177 (85%) patients were between 16–
45 years. HIV status was known for 105/177 (59%) and
in this group 84/105 (80%) patients were HIV positive.
When asked about antibiotic use in the previous three
months, 51/177 (29%) of patients was not able to answer
this question because they were uninformed, physically
unable to answer or because of a combination of the
177 pts
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Figure 1 Study profile. Pts: patients; RS: respiratory syndrome; CXR: chest x-ray; ICT: immunochromatographic test (urine pneumococcal antigen
test); SC: pneumococcal sputum culture; +: positive; -: negative; ND: not done; Colour/pattern boxes: black: definite pneumococcal pneumonia;
grey: probable pneumococcal pneumonia.













1 <0.016 S S I
2 <0.016 S S S
3 0.016 S S R
4 0.016 S S I
5 0.016 S S S
6 0.016 S S I
7 0.016 S S I
8 0.023 S S S
9 0.047 S S R
10 0.047 NS S I
11 0.125 NS S R
12 0.25 NS S R
13 0.75 NS S R
14 0.75 NS S R
15 0.75 NS S R
16 ND NS S I
Minimal inhibitory concentration (MIC) and zone diameter breakpoint
interpretation (BI) of cultured pneumococcal strains, as measured by E-test
(penicillin) and disc diffusion method (oxacillin, erythromycin, co-trimoxazole),
respectively. S: susceptible; NS: non-susceptible; R: resistant. In pneumonia,
when a dose of 1.2 g (2 million IU) × 4 is used, isolates with MIC ≤0.5 mg/L
should be regarded as susceptible to benzyl penicillin; with a dose of 2.4 g × 4
or 1.3 g × 6, isolates with MIC ≤1 mg/L should be regarded as susceptible; and
with a dose of 2.4 g × 6, isolates with MIC ≤2 mg/L should be regarded as
susceptible [8]. Not done: ND.
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otics and another 78/177 (44%) denied its use. 30/177
(17%) of patients were receiving antibiotics at the time of
study inclusion. Although the name ‘penicillin’ was often
mentioned in this group (70%), it was not possible to ver-
ify this information in most cases. 13/177 (7%) of patients
were found to be on TB treatment at study inclusion.
Chest x-rays, culture results and urinary antigen testing
53/170 (31%) patients had a positive urinary antigen test.
In 124 patients a CXR was done. 86/124 (69%) patients
had a positive CXR and were therefore qualified as ha-
ving suspected pneumonia. 35 of these 86 (41%) patients
turned out to have pneumococcal pneumonia, based on
a positive culture and/or a positive urinary antigen test.
An additional 6 patients had a positive culture and a
positive urinary antigen test in the absence of a positive
CXR, so overall, 41/177 (23%) patients with a respiratory
syndrome fulfilled the criteria of either definite or prob-
able pneumococcal pneumonia (Figure 1).
A total of 166 sputum samples were collected and sub-
sequent culture yielded 16 pneumococcal strains (Table 1).
One mg oxacillin disc testing identified potential penicillin
resistance in 7/16 (44%) strains. One pneumococcal strain
did not survive for further testing and as a result, MICs
were measured for 15 pneumococcal strains using the
E-test. Benzyl penicillin MICs ranged from <0.016 to
0.75 mg/L. No isolates were found to be resistant to peni-
cillin (MIC >2.0 mg/L). However, 3/15 (20%) pneumococ-
cal strains had MICs >0.5 mg/L, and would classify as
non-susceptible when a dose of penicillin of 1.2 g (2 mil-
lion IU) 4 times daily or less is used. Based on disc diffu-
sion testing a 100% susceptibility rate was observed for
erythromycin, whereas 7/13 (44%) strains were resistant to
co-trimoxazole.Discussion
Our study presents the first data concerning susceptibil-
ity to commonly used antibiotics in adult pneumococcal
pneumonia in urban Mozambique. As expected, our
study population mainly consisted of young adults with
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able pneumonia patients diagnosed with pneumococcal
pneumonia, the proportion of pneumonia attributable
to pneumococcus was apparently high. All cultured
pneumococcal strains were found to be penicillin sus-
ceptible, but 3/15 strains had penicillin MICs > 0.5 mg/L,
for which dose specific clinical breakpoints apply, accor-
ding to the EUCAST recommendations.
The estimated high contribution of S. pneumoniae to
the local burden of pneumonia as found in our study
seems to match the results of etiological studies in
Africa, where S. pneumoniae was the most common
causative agent, being found in 31-46% of pneumo-
nia cases [9-11].
After a critical appraisal of microbiological, pharmaco-
kinetic and pharmacodynamic data, as well as clinical
studies on the use of penicillin in non-meningeal
pneumococcal infection, current penicillin MIC break-
points for treatment of non-meningeal S. pneumoniae
infections from the American Clinical and Laboratory
Standards Institute (CLSI) have been expanded and re-
set at ≤2 mg/L (susceptible) and ≥8 mg/L (resistant) in
2008 [12]. In contrast, for pneumonia, EUCAST cate-
gorizes pneumococcal strains with MICs >2 mg/L as
resistant while recommending dosage specific MIC
breakpoints for strains with MICs ≤ 2 mg/L. EUCAST
suggests for each country to apply the breakpoints
appropriate for the dosage of benzyl penicillin most
often used [8].
As for adult benzyl penicillin treatment in Mozambique,
the national formulary recommends the use of ‘1 million
International Units (IU) or more, 4–6 times daily’ for
non-meningeal infections [13]. MICs as measured in our
study do justify the continued use of penicillin in adult
pneumococcal pneumonia in our setting. However,
current EUCAST’s interpretation of clinical MIC
breakpoints supports the use of a standard dosage that
would be effective against all strains with penicillin
MICs within the observed range, i.e. 2.4 g (4 million IU) 4
times daily or 1.2 g (2 million IU) 6 times daily (Table 1).
Pneumococcal susceptibility rates appear to vary
across Africa, but a comparison of data is complicated
by the use of different antimicrobial susceptibility testing
methods and interpretive criteria. In a recent systematic
review on community acquired bloodstream infections
in Africa, 9.7% (range 0-36%) of pneumococcal isolates
was resistant to ampicillin, 40% to co-trimoxazole and 2%
to erythromycin [14]. South Africa, -one of Mozambique’s
neighbouring countries-, reported the most impressive
pneumococcal resistance rates in the region with 25-
50% of isolates being resistant to penicillin (MIC >2 mg/L)
[15]. In contrast, in neighbouring Malawi, hospital sur-
veillance data demonstrated that the rate of potential
penicillin non-susceptibility based on disc diffusiontesting in invasive pneumococcal strains has been ap-
proximately 10% since 2005, which appears to be lower
than the rate found in our study [16]. However, in this
study, MICs were not determined. Co-trimoxazole resist-
ance is common in Africa and our study results are not
different in this respect [17].
Our results have to be interpreted with caution as the
pneumococcal culture sample size was small and a posi-
tive sputum culture may represent colonization rather
than infection, although we believe that this risk is low
as we selected patients on the basis of a clinical syn-
drome in combination with radiologic and microbio-
logical criteria.
In conclusion, the proportion of pneumonia attribut-
able to pneumococcus was high in adults in an urban re-
ferral hospital in Mozambique. All pneumococcal strains
turned out to be penicillin susceptible as based on benzyl
penicillin MIC results and there seems to be no need to
abandon penicillin as the main treatment for pneumo-
coccal pneumonia. At the same time, given the presence
of strains with MICs > 0.5 mg/L, current standard peni-
cillin dosing for pneumonia may be insufficient. For
Mozambique, as well as for other sub-Saharan African
countries, we would like to emphasize the need for the
use of a standard dosage that would be effective against
strains with penicillin MICs within the locally observed
range. More extensive, continued monitoring is needed
to guide prudent empiric antibiotic choices.
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